Karen S Fernández1, Cindy L Schwartz2, Lu Chen3, Louis S Constine4, Allen Chauvenet5, Pedro A de Alarcón6. 1. Valley Children's Healthcare, Cancer and Blood Disorders Center, Madera, California. 2. Children's Hospital of Wisconsin, Milwaukee, WI. 3. City of Hope and Beckman Research Institute, Duarte, California. 4. University of Rochester Medical Center, Rochester, New York. 5. Department of Pediatrics, West Virginia University, Charleston, West Virginia. 6. University of Illinois College of Medicine at Peoria, Peoria, Illinois.
Abstract
PURPOSE: We evaluated the outcome of children (<15 years) versus that of adolescents and young adults (AYA; 15-≤ 21 years) treated for Hodgkin lymphoma (HL) in two Pediatric Oncology Group/Children's Oncology Group clinical trials, P9425 and P9426, that used dose-dense, response-based chemotherapy and reduced dose radiotherapy. PATIENTS AND METHODS: Subjects 21 years or younger with HL were eligible for these studies. Subjects with low-risk (stages IA, IIA, and IIIA1) without large mediastinal adenopathy biopsy-proven HL, eligible for P9426, were treated with two to four 28-day cycles of doxorubicin, bleomycin, vincristine, and etoposide (ABVE) chemotherapy and 25.5 Gy of involved field radiotherapy. Subjects with intermediate-risk (stages IB, IIA, IIIA1 with large mediastinal adenopathy, and IIIA2) and high-risk (stages IIB, IIIB, and IV) biopsy-proven HL, eligible for P9425, were treated with three to five 21-day cycles of ABVE plus prednisone and cyclophosphamide (ABVE-PC) chemotherapy and 21 Gy of involved region radiotherapy. We compared the 5-year event-free survival (EFS), based on Kaplan-Meier product-limit method, of children versus that of AYA. RESULTS: Four hundred seventy-one subjects were enrolled on P9425 and P9426 combined. Of these subjects, 203 were AYA, 104 with intermediate and high-risk HL, and 99 with low-risk HL. The 5-year EFS of children did not significantly differ from that of AYA (85.9 vs. 87.1%) with a median follow up of 7.7 years (P = 0.51). CONCLUSION: Given the equivalent and excellent results of therapy, HL represents an opportunity for adult and pediatric cancer treatment collaborative groups to jointly design clinical trials targeted to AYA. These trials should focus on both treatment efficacy and the quality of life of AYA while receiving chemotherapy and in reduction of long-term side effects in the survivorship years.
PURPOSE: We evaluated the outcome of children (<15 years) versus that of adolescents and young adults (AYA; 15-≤ 21 years) treated for Hodgkin lymphoma (HL) in two Pediatric Oncology Group/Children's Oncology Group clinical trials, P9425 and P9426, that used dose-dense, response-based chemotherapy and reduced dose radiotherapy. PATIENTS AND METHODS: Subjects 21 years or younger with HL were eligible for these studies. Subjects with low-risk (stages IA, IIA, and IIIA1) without large mediastinal adenopathy biopsy-proven HL, eligible for P9426, were treated with two to four 28-day cycles of doxorubicin, bleomycin, vincristine, and etoposide (ABVE) chemotherapy and 25.5 Gy of involved field radiotherapy. Subjects with intermediate-risk (stages IB, IIA, IIIA1 with large mediastinal adenopathy, and IIIA2) and high-risk (stages IIB, IIIB, and IV) biopsy-proven HL, eligible for P9425, were treated with three to five 21-day cycles of ABVE plus prednisone and cyclophosphamide (ABVE-PC) chemotherapy and 21 Gy of involved region radiotherapy. We compared the 5-year event-free survival (EFS), based on Kaplan-Meier product-limit method, of children versus that of AYA. RESULTS: Four hundred seventy-one subjects were enrolled on P9425 and P9426 combined. Of these subjects, 203 were AYA, 104 with intermediate and high-risk HL, and 99 with low-risk HL. The 5-year EFS of children did not significantly differ from that of AYA (85.9 vs. 87.1%) with a median follow up of 7.7 years (P = 0.51). CONCLUSION: Given the equivalent and excellent results of therapy, HL represents an opportunity for adult and pediatric cancer treatment collaborative groups to jointly design clinical trials targeted to AYA. These trials should focus on both treatment efficacy and the quality of life of AYA while receiving chemotherapy and in reduction of long-term side effects in the survivorship years.
Authors: Debra L Friedman; Lu Chen; Suzanne Wolden; Allen Buxton; Kathleen McCarten; Thomas J FitzGerald; Sandra Kessel; Pedro A De Alarcon; Allen R Chen; Nathan Kobrinsky; Peter Ehrlich; Robert E Hutchison; Louis S Constine; Cindy L Schwartz Journal: J Clin Oncol Date: 2014-10-13 Impact factor: 44.544
Authors: Dennis A Eichenauer; Henning Bredenfeld; Heinz Haverkamp; Horst Müller; Jeremy Franklin; Michael Fuchs; Peter Borchmann; Hans-Konrad Müller-Hermelink; Hans T Eich; Rolf-Peter Müller; Volker Diehl; Andreas Engert Journal: J Clin Oncol Date: 2009-11-09 Impact factor: 44.544
Authors: Cameron K Tebbi; Nancy P Mendenhall; Wendy B London; Jonathan L Williams; Robert E Hutchison; Thomas J Fitzgerald; Pedro A de Alarcón; Cindy Schwartz; Allen Chauvenet Journal: Pediatr Blood Cancer Date: 2012-08-21 Impact factor: 3.167
Authors: Cindy L Schwartz; Louis S Constine; Doojduen Villaluna; Wendy B London; Robert E Hutchison; Richard Sposto; Steven E Lipshultz; Charles S Turner; Pedro A deAlarcon; Allen Chauvenet Journal: Blood Date: 2009-07-07 Impact factor: 22.113
Authors: Volker Diehl; Jeremy Franklin; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Dirk Hasenclever; Hans Tesch; Richard Herrmann; Bernd Dörken; Hans-Konrad Müller-Hermelink; Eckhardt Dühmke; Markus Loeffler Journal: N Engl J Med Date: 2003-06-12 Impact factor: 91.245
Authors: Justine M Kahn; Qinglin Pei; Debra L Friedman; Joel Kaplan; Frank G Keller; David Hodgson; Yue Wu; Burton E Appel; Smita Bhatia; Tara O Henderson; Cindy L Schwartz; Kara M Kelly; Sharon M Castellino Journal: Lancet Haematol Date: 2022-01 Impact factor: 18.959
Authors: Esmée C de Baat; Renée L Mulder; Saro Armenian; Elizabeth Am Feijen; Heynric Grotenhuis; Melissa M Hudson; Annelies Mc Mavinkurve-Groothuis; Leontien Cm Kremer; Elvira C van Dalen Journal: Cochrane Database Syst Rev Date: 2022-09-27